DailyIQ
|
Sector:HealthcareAll sectors
Last updated 5 minutes ago

JNJ·Johnson & Johnson

$.
-. (-.%)
After Hours
High
$261.30
Open
$260.19
Market Cap
619.69B
52W High
$269.43
Low
$255.52
P. Close
$257.01
P/E
29.45
52W Low
$154.80
Fwd P/E
20.16
DailyIQ Est.
$266.95
Technical Score (1D)
82
BUY
News Sentiment
61
BULLISH
The Illinois Appellate Court upheld a $45 million talc verdict against Johnson & Johnson, confirming the original jury decision. This reinforces the company’s legal exposure and could influence future liability estimates, so traders should monitor subsequent litigation developments and regulatory actions. The court’s affirmation also applies to Kenvue, heightening scrutiny of both firms’ talc product lines. In the broader earnings context, JNJ is among the 70 companies reporting Q2 results, and analysts expect upward earnings revisions across the S&P 500, which may buoy investor confidence in JNJ’s upcoming guidance. Watch how JNJ’s guidance aligns with the broader market expectations. BofA Securities has raised its 12‑month price target to $263 from $254, citing a stronger earnings outlook and a robust product pipeline, signaling confidence in JNJ’s earnings trajectory amid competitive pressures. Pay attention to the upcoming earnings release and any guidance updates that could validate the new target. The Q2 earnings preview highlights revenue growth, operating margin trends, and product launch guidance, especially in consumer health and medical devices, which will shape the company’s profitability trajectory and could affect its valuation. Monitor earnings surprises, guidance revisions, and regulatory approvals that could impact results.
Earnings Summary
Johnson & Johnson is a diversified global healthcare leader operating through its Innovative Medicine and MedTech segments, delivering prescription drugs across immunology, oncology, neuroscience and cardiovascular spaces while also supplying a broad array of medical devices for electrophysiology, orthopedics, surgery and vision care. In the most recent reporting cycle, the company posted Q1 2026 revenue of $24.062 billion and EPS of $2.70, slightly below the $2.88 estimate, following a Q4 2025 revenue of $24.564 billion and EPS of $2.46 that narrowly missed its $2.4624 forecast; the prior quarter, Q3 2025, saw revenue of $23.993 billion and EPS of $2.80, comfortably beating the $2.7589 estimate, and Q2 2025 delivered $23.743 billion and $2.77 EPS versus a $2.684 forecast, while Q1 2025 posted $21.893 billion and $2.77 EPS against a $2.579 forecast. Thus, the company has achieved four consecutive earnings surprises in the last five quarters, with revenue growth accelerating from $22.52 billion in Q4 2024 to $24.564 billion in Q4 2025 (≈9.2% YoY) before a modest dip in Q1 2026, followed by a projected rebound in Q2 2026 revenue to $25.289 billion. Historically, JNJ has maintained a steady upward trajectory in revenue year‑over‑year, consistently beating analyst expectations in most periods, though recent misses in Q4 2025 and Q1 2026 suggest a potential short‑term slowdown. Recent FDA approvals—including the Dual Energy THERMOCOOL SMARTTOUCH SF ablation platform and the Dual Energy ablation catheter—expand the MedTech portfolio into high‑margin electrophysiology and interventional cardiology, offering new revenue streams that may offset earnings volatility; the company’s strong dividend record and AI‑driven product pipeline also reinforce its appeal to income‑focused investors. Going forward, investors should watch the Q2 2026 earnings release for early revenue recognition from the newly approved devices, any updates to reimbursement or pricing that could accelerate adoption, and guidance revisions that may reflect the impact of these product launches on the company’s growth outlook.

EPS

EstBeatMiss
$2.40$2.53$2.67$2.81$2.95Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.86 - -
Q1'26$2.88$2.70-6.4%
Q4'25$2.46$2.46-0.1%
Q3'25$2.76$2.80+1.5%
Q2'25$2.68$2.77+3.2%
Q1'25$2.58$2.77+7.4%

Revenue

EstBeatMiss
$21.4B$22.5B$23.6B$24.7B$25.8BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$25.3B - -
Q1'26$25.0B$24.1B-3.9%
Q4'25$24.4B$24.6B+0.7%
Q3'25 - $24.0B -
Q2'25 - $23.7B -
Q1'25 - $21.9B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

JNJ Stock Snapshot

JNJ is currently trading at $257.15, giving Johnson & Johnson a market cap of 619.69B and a P/E ratio of 29.4. Today's range spans $255.52–$261.30, with shares opening at $260.19 and moving up $0.14 (0.1%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 61/100.

Over the past year JNJ has traded between $154.80 and $269.43 - the current price is +66.1% off the 52-week low and -4.6% from the high. 33 analysts cover the stock with a Buy consensus and a mean 12-month target of $258.59 (range $190.00–$298.00), implying upside of +0.6%.

Quant strategies weight JNJ heavily in their Healthcare universe - 619.69B in capitalization, 82/100 technical score (BUY), bullish sentiment (61/100). Price: $257.15 (near 52-week highs). The current P/E ratio stands at 29.4. The 52-week span of $154.80–$269.43 shows a stock that knows how to trend when conditions align, and the current setup is exactly what systematic models are designed to identify and act on - before the broader market consensus shifts.

From a positioning standpoint, JNJ's BUY reading at 619.69B in capitalization means that even marginal increases in institutional allocation produce outsized dollar inflows — the kind that sustain price trends rather than just spike them. News sentiment at 61/100 (bullish) adds a secondary confirmation layer that active managers increasingly factor into systematic entry rules.